Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 97

1.

PLEKHA5 as a Biomarker and Potential Mediator of Melanoma Brain Metastasis.

Jilaveanu LB, Parisi F, Barr ML, Zito CR, Cruz-Munoz W, Kerbel RS, Rimm DL, Bosenberg MW, Halaban R, Kluger Y, Kluger HM.

Clin Cancer Res. 2015 May 1;21(9):2138-47. doi: 10.1158/1078-0432.CCR-14-0861. Epub 2014 Oct 14.

2.

PLEKHA5: A Key to Unlock the Blood-Brain Barrier?

Eisele SC, Gill CM, Shankar GM, Brastianos PK.

Clin Cancer Res. 2015 May 1;21(9):1978-80. doi: 10.1158/1078-0432.CCR-14-2604. Epub 2015 Mar 16.

3.

Molecular basis for the critical role of suppressor of cytokine signaling-1 in melanoma brain metastasis.

Huang FJ, Steeg PS, Price JE, Chiu WT, Chou PC, Xie K, Sawaya R, Huang S.

Cancer Res. 2008 Dec 1;68(23):9634-42. doi: 10.1158/0008-5472.CAN-08-1429.

4.

Targeting hyperactivation of the AKT survival pathway to overcome therapy resistance of melanoma brain metastases.

Niessner H, Forschner A, Klumpp B, Honegger JB, Witte M, Bornemann A, Dummer R, Adam A, Bauer J, Tabatabai G, Flaherty K, Sinnberg T, Beck D, Leiter U, Mauch C, Roesch A, Weide B, Eigentler T, Schadendorf D, Garbe C, Kulms D, Quintanilla-Martinez L, Meier F.

Cancer Med. 2013 Feb;2(1):76-85. doi: 10.1002/cam4.50. Epub 2013 Feb 3.

5.

Characterization of PD-L1 Expression and Associated T-cell Infiltrates in Metastatic Melanoma Samples from Variable Anatomic Sites.

Kluger HM, Zito CR, Barr ML, Baine MK, Chiang VL, Sznol M, Rimm DL, Chen L, Jilaveanu LB.

Clin Cancer Res. 2015 Jul 1;21(13):3052-60. doi: 10.1158/1078-0432.CCR-14-3073. Epub 2015 Mar 18.

6.

Deciphering mechanisms of brain metastasis in melanoma - the gist of the matter.

Redmer T.

Mol Cancer. 2018 Jul 27;17(1):106. doi: 10.1186/s12943-018-0854-5. Review.

7.

Molecular Pathways Mediating Metastases to the Brain via Epithelial-to-Mesenchymal Transition: Genes, Proteins, and Functional Analysis.

Jeevan DS, Cooper JB, Braun A, Murali R, Jhanwar-Uniyal M.

Anticancer Res. 2016 Feb;36(2):523-32.

PMID:
26851006
8.

Identification and characterization of splicing variants of PLEKHA5 (Plekha5) during brain development.

Yamada K, Nomura N, Yamano A, Yamada Y, Wakamatsu N.

Gene. 2012 Jan 15;492(1):270-5. doi: 10.1016/j.gene.2011.10.018. Epub 2011 Oct 20.

PMID:
22037487
9.

Gene expression profiles of human melanoma cells with different invasive potential reveal TSPAN8 as a novel mediator of invasion.

Berthier-Vergnes O, El Kharbili M, de la Fouchardière A, Pointecouteau T, Verrando P, Wierinckx A, Lachuer J, Le Naour F, Lamartine J.

Br J Cancer. 2011 Jan 4;104(1):155-65. doi: 10.1038/sj.bjc.6605994. Epub 2010 Nov 16.

10.

A miRNA-Based Signature Detected in Primary Melanoma Tissue Predicts Development of Brain Metastasis.

Hanniford D, Zhong J, Koetz L, Gaziel-Sovran A, Lackaye DJ, Shang S, Pavlick A, Shapiro R, Berman R, Darvishian F, Shao Y, Osman I, Hernando E.

Clin Cancer Res. 2015 Nov 1;21(21):4903-12. doi: 10.1158/1078-0432.CCR-14-2566. Epub 2015 Jun 18.

11.

The metastatic microenvironment: brain-residing melanoma metastasis and dormant micrometastasis.

Izraely S, Sagi-Assif O, Klein A, Meshel T, Tsarfaty G, Pasmanik-Chor M, Nahmias C, Couraud PO, Ateh E, Bryant JL, Hoon DS, Witz IP.

Int J Cancer. 2012 Sep 1;131(5):1071-82. doi: 10.1002/ijc.27324. Epub 2011 Dec 2.

12.

Increased expression of melanoma stem cell marker CD271 in metastatic melanoma to the brain.

Guo R, Fierro-Fine A, Goddard L, Russell M, Chen J, Liu CZ, Fung KM, Hassell LA.

Int J Clin Exp Pathol. 2014 Dec 1;7(12):8947-51. eCollection 2014.

13.

Mda-9/syntenin is expressed in uveal melanoma and correlates with metastatic progression.

Gangemi R, Mirisola V, Barisione G, Fabbi M, Brizzolara A, Lanza F, Mosci C, Salvi S, Gualco M, Truini M, Angelini G, Boccardo S, Cilli M, Airoldi I, Queirolo P, Jager MJ, Daga A, Pfeffer U, Ferrini S.

PLoS One. 2012;7(1):e29989. doi: 10.1371/journal.pone.0029989. Epub 2012 Jan 13.

14.

MAP kinase activity supported by BRAF (V600E) mutation rather than gene amplification is associated with ETV1 expression in melanoma brain metastases.

Birner P, Berghoff AS, Dinhof C, Pirker C, Capper D, Schoppmann SF, Petzelbauer P, von Deimling A, Berger W, Preusser M.

Arch Dermatol Res. 2014 Dec;306(10):873-84. doi: 10.1007/s00403-014-1490-6. Epub 2014 Jul 30.

PMID:
25073704
15.

Inhibition of melanoma brain metastasis by targeting melanotransferrin at the cell surface.

Rolland Y, Demeule M, Fenart L, Béliveau R.

Pigment Cell Melanoma Res. 2009 Feb;22(1):86-98. doi: 10.1111/j.1755-148X.2008.00525.x. Epub 2008 Dec 1.

PMID:
19017294
16.

The metastatic microenvironment: Brain-derived soluble factors alter the malignant phenotype of cutaneous and brain-metastasizing melanoma cells.

Klein A, Sagi-Assif O, Izraely S, Meshel T, Pasmanik-Chor M, Nahmias C, Couraud PO, Erez N, Hoon DS, Witz IP.

Int J Cancer. 2012 Dec 1;131(11):2509-18. doi: 10.1002/ijc.27552. Epub 2012 Apr 12.

17.

Molecular and genetic diversity in the metastatic process of melanoma.

Harbst K, Lauss M, Cirenajwis H, Winter C, Howlin J, Törngren T, Kvist A, Nodin B, Olsson E, Häkkinen J, Jirström K, Staaf J, Lundgren L, Olsson H, Ingvar C, Gruvberger-Saal SK, Saal LH, Jönsson G.

J Pathol. 2014 May;233(1):39-50. doi: 10.1002/path.4318. Epub 2014 Jan 27.

18.

Interleukin 10 suppresses tumor growth and metastasis of human melanoma cells: potential inhibition of angiogenesis.

Huang S, Xie K, Bucana CD, Ullrich SE, Bar-Eli M.

Clin Cancer Res. 1996 Dec;2(12):1969-79.

19.

Expression profiling reveals that methylation of TIMP3 is involved in uveal melanoma development.

van der Velden PA, Zuidervaart W, Hurks MH, Pavey S, Ksander BR, Krijgsman E, Frants RR, Tensen CP, Willemze R, Jager MJ, Gruis NA.

Int J Cancer. 2003 Sep 10;106(4):472-9. Erratum in: Int J Cancer. 2004 Oct 10;111(6):982.

20.

RASSF6 exhibits promoter hypermethylation in metastatic melanoma and inhibits invasion in melanoma cells.

Mezzanotte JJ, Hill V, Schmidt ML, Shinawi T, Tommasi S, Krex D, Schackert G, Pfeifer GP, Latif F, Clark GJ.

Epigenetics. 2014 Nov;9(11):1496-503. doi: 10.4161/15592294.2014.983361.

Supplemental Content

Support Center